The Food and Drug Administration yesterday released comparative performance data for 55 COVID-19 molecular diagnostic tests.

Test developers are required to assess their test’s performance against a reference panel of viral samples to receive emergency use authorization.

In the data, a lower product LoD (limit of detection) indicates a test’s ability to detect a smaller amount of viral material in a given sample, signaling a more sensitive test. FDA plans to update the data as it receives additional results to help inform laboratories, health care providers and patients about the relative performance of available tests.

In other news this week, FDA awarded a research contract to the University of Liverpool and global partners to sequence and analyze SARS-CoV-2 and other coronavirus samples to help inform the real-time performance of molecular-based diagnostics.

Related News Articles

Headline
Proactive COVID-19 testing of all long-term care staff and residents, who are usually at higher risk of contracting the virus, may help prevent potential…
Headline
The Food and Drug Administration yesterday approved a new drug application for propofol injectable emulsion, an intravenous general anesthetic and sedation…
Headline
In a sample of 598 hospitalized pregnant women with COVID-19, 55% had no symptoms on admission, according to a report released this week by the Centers for…
Headline
The Centers for Disease Control and Prevention today updated its testing guidance for SARS-CoV-2, the virus that causes COVID-19. “Due to the significance of…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response recently posted new and updated COVID-19 resources…
Headline
The Food and Drug Administration this week approved dexmedetomidine hydrochloride in 0.9% sodium chloride injection for the sedation of initially intubated and…